US Medical device giant Axonics has announced that it has secured market clearance from Australia’s Therapeutic Goods Administration (TGA) for its R20 rechargeable sacral neuromodulation (SNM) system ...

Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...

Axonics Inc. will soon make its television debut in an ad campaign about its therapies to treat bowel and urinary incontinence, company executives say. According to Axonics CEO Raymond Cohen, the ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20 ® ...

It’s finally over. Medtronic and Boston Scientific’s Axonics longstanding patent battle is finished. The companies settled the legal spat over patent infringements related to sacral neuromodulation ...

Axonics, Inc.'s (NASDAQ:AXNX) Chief Financial Officer, Kari Leigh Keese, has executed a sale of company stock valued at more than $205,000, according to a recent SEC filing. The transactions, which ...

Weighted-average shares used to compute basic and diluted net loss per share ...

Axonics, Inc., based in Irvine, California, specializes in the development and commercialization of innovative medical devices and is known for its surgical and medical instruments and apparatus. The ...